biologic

Casgevy

Exagamglogene autotemcel

Loss of exclusivityDecember 2035projected — 12-year biologic exclusivity estimate
CompanyVertex Pharmaceuticals Inc

Drug detail

Brand nameCasgevy
Active ingredientExagamglogene autotemcel
Strength4-13 × 10^6 CELL/ML
Dosage formSuspension
RouteIntravenous
ModalityBiologic
FDA approvalDecember 2023
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Casgevy patent cliff — loss of exclusivity December 2035 | CliffBio